Literature DB >> 3609069

Biliary excretion of olsalazine sodium in humans.

M Ryde, S Gustavsson.   

Abstract

The biliary excretion of Olsalazine sodium (ADS) was studied by three different methods in healthy volunteers and in patients. 1 g ADS in a 2% solution was infused during 1 h into jejunum in six healthy volunteers via a three lumen sond. The bile was collected, during 2.5-6 h, proximal of an occlusive balloon on the three lumen sond. 10 mg ADS was given i.v. to five healthy volunteers and the bile was collected during 3-4.5 h with the same type of three lumen sond as used in the first experiment. 1 g ADS was given orally to three patients, with a T-tube inserted into coleducus at surgery. The bile was collected via the T-tube for 24 h. The mean biliary excretion of the jejunal dose was 0.41% (0.22% if one subject, who probably had a beckflow of the instillation fluid, is omitted). In patients, the mean excretion with bile of ADS was 0.35% and of ac-5-ASA 0.17%. Due to the short collection time after jejunal infusion and the probably incomplete collection of bile in both enteral studies the biliary excretion was estimated to be less than 2% as ADS and less than 1% as ac-5-ASA. The biliary excretion of an i.v. dose showed large individual variations (0.16-12.2%) which were not correlated to the length of the collection time. The total excretion was estimated to be less than 20% as ADS. No metabolites were detected after the i.v. dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609069     DOI: 10.1007/BF03189857

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  18 in total

1.  Bile drainage after choledochostomy in man, with some observations on biliary fistula.

Authors:  F F RUNDLE; M H CASS; B ROBSON; M MIDDLETON
Journal:  Surgery       Date:  1955-06       Impact factor: 3.982

2.  The excretion and concentration of terramycin in the abnormal human biliary tract.

Authors:  J ZASLOW; A ROSENTHAL
Journal:  Ann Surg       Date:  1954-04       Impact factor: 12.969

3.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

4.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

5.  Elimination of azlocillin in patients with biliary t-tube drainage.

Authors:  U Gundert-Remy; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Bile acid output and the interdigestive migrating motor complex in normals and in cholecystectomy patients.

Authors:  T L Peeters; G Vantrappen; J Janssens
Journal:  Gastroenterology       Date:  1980-10       Impact factor: 22.682

7.  Biliary elimination of mezlocillin: an experimental and clinical study.

Authors:  J M Brogard; J Kopferschmitt; J P Arnaud; M Dorner; J La Villaureix
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

Review 8.  Biliary excretion of drugs in man.

Authors:  D E Rollins; C D Klaassen
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

9.  [Ciprofloxacine: evaluation of its biliary elimination in man].

Authors:  J M Brogard; F Jehl; J P Arnaud; P Lévy; F Peladan; J F Blicklé; H Monteil
Journal:  Schweiz Med Wochenschr       Date:  1985-03-30

10.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

View more
  7 in total

1.  Determination of the biliary excretion of piperacillin in humans using a novel method.

Authors:  Giulia Ghibellini; Lakshmi S Vasist; Terence E Hill; William D Heizer; Richard J Kowalsky; Kim L R Brouwer
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  A novel method for the determination of biliary clearance in humans.

Authors:  Giulia Ghibellini; Brendan M Johnson; Richard J Kowalsky; William D Heizer; Kim L R Brouwer
Journal:  AAPS J       Date:  2004-11-23       Impact factor: 4.009

4.  Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs.

Authors:  William J Guiney; Claire Beaumont; Steve R Thomas; Darren C Robertson; Simon M McHugh; Annelize Koch; Duncan Richards
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 5.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 6.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

7.  The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.

Authors:  E M Ryde; N O Ahnfelt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.